Location History:
- Sangus, MA (US) (1997)
- Saugus, MA (US) (2004 - 2008)
- Glouchester, MA (US) (2016)
- Gloucester, MA (US) (2017)
Company Filing History:
7 out of 2,882 
2 out of 269 
Years Active: 1997-2017
Title: The Innovations of David T. MacLaughlin: Pioneering Ovarian Cancer Research
Introduction: David T. MacLaughlin, based in Saugus, MA, has made significant contributions to the field of biomedical research with a focus on ovarian cancer. With a total of seven patents to his name, his work has paved the way for novel treatments and methodologies aimed at improving the diagnosis and treatment of this challenging disease.
Latest Patents: MacLaughlin's recent patents address critical advancements in the understanding and treatment of ovarian cancer stem cells. One notable invention pertains to the isolation and methodologies related to a specific subpopulation of ovarian cancer stem cells. This population is identified as CD44+/CD24+/EpCam+/ECad^- and is particularly responsive to chemotherapeutic agents while being inhibited by Mullerian Inhibiting Substance (MIS) and its mimetics. Furthermore, his inventions provide comprehensive methods to screen ovarian cancer patients for these stem cell populations, allowing for targeted treatment strategies.
Another patent highlights the methods for treating and preventing ovarian cancer in a subject by administering effective doses of Mullerian Inhibiting Substance or agents that inhibit BCRP1. This patent also emphasizes identifying and enriching populations of both ovarian cancer stem cells and somatic ovarian stem cells, which can significantly advance therapeutic approaches. By detailing these methodologies and identifying specific markers, MacLaughlin's work offers hope for better-targeted therapies in ovarian cancer treatment.
Career Highlights: Throughout his career, David T. MacLaughlin has collaborated with notable institutions that have fostered innovation and research. He has been associated with The General Hospital Corporation and the University of Medicine and Dentistry of New Jersey, where he has contributed to important studies and clinical applications aimed at combating ovarian cancer.
Collaborations: MacLaughlin has worked alongside distinguished colleagues in the field, including Patricia K. Donahoe and Joseph P. Vacanti, both of whom have made their mark in medical research. These collaborations have not only enhanced his work but have also contributed broadly to the scientific community's understanding of cancer stem cells and their implications in treatment.
Conclusion: David T. MacLaughlin continues to be a prominent figure in ovarian cancer research, with numerous patents illustrating his commitment to innovation in the medical field. His foundational work in identifying and treating ovarian cancer stem cells through advanced methodologies stands as a testament to his dedication and expertise. As research progresses, MacLaughlin’s contributions will likely influence future treatments and improve patient outcomes in the fight against ovarian cancer.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.